CHOLINE C-11
Peakcholine c-11
NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
CHOLINE C-11 (choline c-11) is radiopharmaceutical activity [moa]. Approved for prostate cancer. First approved in 2012.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Choline C-11 is a radioactive diagnostic agent administered intravenously for positron emission tomography (PET) imaging. It is used to detect prostate cancer by visualizing choline uptake in tumor cells. The drug works as a radiopharmaceutical that localizes to areas of increased cellular metabolism characteristic of malignant prostate tissue.
Peak
Product is in peak commercial phase; teams are typically stabilized with focus on market share defense rather than growth expansion.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Career Relevance
Choline C-11 roles focus on market defense and reimbursement optimization in a maturing, competitive diagnostic imaging space. Professionals joining this team should expect responsibility for maintaining market share against superior competitors rather than driving category expansion.
Regional Sales Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.